Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience

Creative Commons License

Ceylan B., Calica A., AK Ö., AKKOYUNLU Y., Turhan V.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.17, no.10, 2013 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 10
  • Publication Date: 2013
  • Doi Number: 10.1016/j.ijid.2013.02.030
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Crimean-Congo hemorrhagic fever, Ribavirin, ORAL RIBAVIRIN, EFFICACY, VIRUS
  • Kütahya Health Sciences University Affiliated: No


Crimean-Congo hemorrhagic fever (CCHF) is a viral infection associated with a high mortality rate. Ribavirin is the only drug used in the treatment of this disease. Studies investigating the effectiveness of ribavirin in CCHF have been retrospective and to date have included only a small number of cases. In recent years, due to climate changes, the number of cases of CCHF in Turkey has increased, and experience in the treatment of CCHF has improved. Several studies have evaluated the efficacy of ribavirin in Turkey, including one randomized controlled trial and two studies with a large number of cases. In these studies, ribavirin therapy was not shown to decrease mortality rates; the mortality rate was 2-9% in patients treated with ribavirin and 5.6-11% in those who were not treated with this drug. These findings suggest that patients with CCHF should be followed with supportive care only until randomized controlled trials with larger groups have been conducted. (C) 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.